A bill for an act relating to insurance coverage for prescription insulin drugs.
House File 658 would require certain health insurance policies, health maintenance organization contracts, and public employee health plans in Iowa that cover prescription drugs to cap a covered person’s out-of-pocket cost-sharing for insulin at no more than $25 per prescription fill for up to a 31-day supply. The cap would apply to at least one type of each major insulin category: rapid-acting, short-acting, intermediate-acting, and long-acting insulin. The bill defines prescription insulin drugs, cost-sharing, and covered person, and it allows insurers to charge less than the cap if they choose.
The bill applies to policies and plans delivered, issued for delivery, continued, or renewed in Iowa on or after January 1, 2026. It covers individual and group accident and sickness policies, hospital or medical service contracts, HMOs, and public employee plans, while excluding several categories such as accident-only coverage, short-term coverage, Medicare supplement, long-term care, disability income, workers’ compensation, and automobile medical payment insurance. The insurance commissioner would be authorized to adopt rules to administer the new requirements.
HF 658 would amend Iowa insurance law by creating a new section in chapter 514C requiring insulin cost-sharing limits in applicable prescription drug plans. Its practical effect would be to reduce out-of-pocket expenses for insured diabetes patients who use covered insulin products, while imposing a new coverage mandate on insurers and certain public health plans. The bill would also give the insurance commissioner rulemaking authority to implement and enforce the requirement.
The available record shows the bill was introduced and referred to the House Commerce Committee, with no recorded committee transcript, amendment debate, or vote history provided. Based on the text alone, the bill appears to reflect a consumer-protection and affordability approach aimed at lowering insulin costs for people with diabetes. Because there is no documented floor or committee action in the supplied materials, there is no clear evidence of formal support or opposition in the legislative record provided.
The main policy issue likely to generate debate is the mandate itself: insurers and plan sponsors would be required to cap insulin cost-sharing, which could raise concerns about premium impacts, benefit design, and administrative complexity. Another possible point of contention is the scope of coverage, including which insulin products must be capped, which plan types are exempt, and the delayed effective date of January 1, 2026. No specific opposing or supporting arguments are included in the provided transcripts, so any contention can only be inferred from the structure of the bill rather than from recorded discussion.